Modulation of Phosphatase Levels in Mice Liver by Genistein Treatment against Radiation Exposure
1, 2
- 1L.B.S. College of Pharmacy, Jaipur-302004, Rajasthan, India.
- 2Radiation Biology Laboratory, Center for Advanced Studies, Department of Zoology, University of Rajasthan, Jaipur-302004, Rajasthan, India.
CORRESPONDENCE
Ajay Gaur
L.B.S. College of Pharmacy, Jaipur-302004, Rajasthan, India.
Volume 1, Issue 2 · pp. 72-79 · 2009 · DOI:
ABSTRACT
Genistein is a soya isoflavone, which is found naturally in legumes, such as soybeans and chickpeas. The intraperitoneal administration of optimum dose (200 mg/kg body weight) of Genistein before 24 hrs and 15 minutes of irradiation (8 Gy at a dose rate of 1.02 Gy/min) increased the acid phosphatase (by 34.7 ± 12.39%) and decreased the alkaline phosphatase (by 49.59 ± 13.82%) in experimental group as compared to control group in liver of Swiss albino mice. Statistically analyzed survival data produced a dose reduction factor (DRF) = 1.24. The results indicate that Genistein against radiation effect may pave way to the formulation of medicine in radiotherapy for normal tissue and possible against radiomimetic drug induced toxicity. Present study also establishes the fact that Genistein may be used as a radioprotector before and after radiation exposure. Hence the possibility of its use as a radioprotectant and radiotherapeutic drug in accidental conditions or nuclear war conditions can not be ruled out.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Gaur, A., & Bhatia, A. (2009). Modulation of Phosphatase Levels in Mice Liver by Genistein Treatment against Radiation Exposure. Pharmacognosy Research, 1(2), 72-79.
Copyright and licence
© 2009 Author(s)
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. CC BY-NC-SA 4.0
